J.P. Morgan Day One: Novartis Reveals Two Deals, Pfizer's Bad Year, Bristol's Wobbly Growth

Updates Also From Gilead, BioMarin, Bausch+Lomb

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.